Skip to main content

Table 3 Adverse events graded using NCI-CTCAE version 4.03

From: Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial

NCI-CTCAE grade

Grade 1–2

Grade 3–4

During induction chemotherapy (n = 10)

 Anemia

5

1

 Neutropenia

5

3

 Thrombocytopenia

1

0

 Alopecia

3

 

 Mucositis/stomatitis

3

1

 Febrile neutropenia

2

 Nausea

5

2

 Vomiting

1

0

 Fatigue

7

1

 Peripheral neuropathy

2

0